Undisclosed target on Cancer-Associated Fibroblasts

The term "Undisclosed target on Cancer-Associated Fibroblasts" refers to proprietary therapeutic targets identified by biotechnology companies that are located on the surface of or secreted by cancer-associated fibroblasts (CAFs). CAFs are a heterogeneous population of cells within the tumor microenvironment (TME) that play a critical role in promoting tumor growth, extracellular matrix remodeling, and immune evasion. Several companies, most notably Mestag Therapeutics and Cantargia, are developing first-in-class therapies, such as bispecific antibodies (e.g., CAN14) and stromal checkpoint inhibitors (e.g., M402), that target these undisclosed molecules to reprogram the TME and enhance anti-tumor immunity. These targets are often identified through advanced single-cell RNA sequencing and functional screening platforms like Mestag's RAFT platform. While the specific molecular identities remain confidential for competitive reasons, they are generally involved in the "fibroblast-immune conversation" and are being investigated for their potential to overcome resistance to standard immunotherapies like PD-1/PD-L1 inhibitors.

Other names

Proprietary CAF targetUndisclosed stromal targetMestag undisclosed targetCantargia undisclosed targetStromal checkpoint target

The mechanism of action typically involves the use of bispecific antibodies, antibody-drug conjugates (ADCs), or nanobodies to either deplete specific CAF subsets, inhibit their pro-tumorigenic signaling, or leverage them as anchors for localized immune activation within the tumor microenvironment.